Live
FierceBiotechBial bails after Parkinson’s fail, axing asset over phase 2 missClinical OMICsGenome Wide Analysis Broadens Genetic Knowledge of AnxietyFierceBiotechGSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer in lung cancerLabiotechPharma in Spain: why global investors and innovators are moving inEndpoints NewsGSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6BeLifeExperience shapes the transformation of olfactory representations along the cortico-hippocampal pathway10x Genomics Blog10x Genomics (NASDAQ: TXG) grants 8,829 RSUs to director Suliman - Stock Titan10x Genomics Blog10x Genomics (TXG) awards 8,829 RSUs to board director - Stock Titan10x Genomics News10x Genomics (TXG) awards director Kimberly Popovits 8,829 RSUs - Stock Titan10x Genomics News10x Genomics (TXG) director receives 8,829 RSU grant, lifts holdings - Stock Titan10x Genomics News10x Genomics shareholders elect directors and approve proposals at annual meeting - Investing.com10x Genomics Blog10x Genomics shareholders elect directors and approve proposals at annual meeting - Investing.com
BioWorld 9 déc. 2025

GSK goes away, Ideaya synthetic lethality bids in-house again

GSK goes away, Ideaya synthetic lethality bids in-house again

Original
Contenu indisponible. Consultez la source originale.